Alpine Immune Sciences Inc (NASDAQ:ALPN) has received a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $12.80.

A number of equities analysts recently weighed in on the company. ValuEngine raised Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, July 26th. Zacks Investment Research raised Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, July 25th. Oppenheimer assumed coverage on Alpine Immune Sciences in a report on Friday, June 29th. They set an “outperform” rating and a $13.00 price objective on the stock. Citigroup assumed coverage on Alpine Immune Sciences in a report on Thursday, June 28th. They set an “outperform” rating and a $13.00 price objective on the stock. Finally, Raymond James assumed coverage on Alpine Immune Sciences in a report on Monday, August 13th. They set a “buy” rating and a $13.00 price objective on the stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. DRW Securities LLC grew its position in Alpine Immune Sciences by 138.7% during the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 14,143 shares during the last quarter. Renaissance Technologies LLC grew its position in Alpine Immune Sciences by 20.9% during the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after acquiring an additional 21,124 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Alpine Immune Sciences by 122.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 18,052 shares during the last quarter. Institutional investors and hedge funds own 56.87% of the company’s stock.

Shares of NASDAQ ALPN remained flat at $$5.00 during trading hours on Friday. The company had a trading volume of 43,193 shares, compared to its average volume of 18,307. The stock has a market cap of $87.65 million, a PE ratio of -4.17 and a beta of 0.54. The company has a current ratio of 20.99, a quick ratio of 20.99 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a 52 week low of $4.89 and a 52 week high of $12.24.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.13). The firm had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $0.30 million. Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 26.00%. As a group, sell-side analysts anticipate that Alpine Immune Sciences will post -2.12 earnings per share for the current fiscal year.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Read More: Initial Public Offering (IPO)

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.